1 |
Zouboulis CC, Chernyshov PV. Hidradenitis suppurativa-specific, patient-reported outcome measures. J Eur Acad Dermatol Venereol 2021;35:1420-1. [PMID: 34139050 DOI: 10.1111/jdv.17306] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
2 |
Kirsten N, Frings V, Nikolakis GD, Presser D, Goebeler M, Zouboulis CC, Augustin M. [Epidemiology, patient quality of life, and treatment costs of hidradenitis suppurativa/acne inversa]. Hautarzt 2021;72:651-7. [PMID: 34223939 DOI: 10.1007/s00105-021-04851-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
3 |
Krajewski PK, Marrón SE, Gomez-Barrera M, Tomas-Aragones L, Gilaberte-Calzada Y, Szepietowski JC. The Use of HSQoL-24 in an Assessment of Quality-of-Life Impairment among Hidradenitis Suppurativa Patients: First Look at Real-Life Data. J Clin Med 2021;10:5446. [PMID: 34830727 DOI: 10.3390/jcm10225446] [Reference Citation Analysis]
|
4 |
Scala E, Cacciapuoti S, Garzorz-Stark N, Megna M, Marasca C, Seiringer P, Volz T, Eyerich K, Fabbrocini G. Hidradenitis Suppurativa: Where We Are and Where We Are Going. Cells 2021;10:2094. [PMID: 34440863 DOI: 10.3390/cells10082094] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
5 |
Krajewski PK, Marrón SE, Tomas Aragones L, Gilaberte-Calzada Y, Szepietowski JC. Self-Reported Hidradenitis Suppurativa Severity: Is It Useful for Clinical Practice? Dermatol Ther (Heidelb) 2022. [PMID: 35274220 DOI: 10.1007/s13555-022-00701-5] [Reference Citation Analysis]
|
6 |
Shukla R, Karagaiah P, Patil A, Farnbach K, Ortega-Loayza AG, Tzellos T, Szepietowski JC, Giulini M, Schepler H, Grabbe S, Goldust M. Surgical Treatment in Hidradenitis Suppurativa. J Clin Med 2022;11:2311. [PMID: 35566438 DOI: 10.3390/jcm11092311] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|